Compare PAR & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | ABUS |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 848.8M |
| IPO Year | 1995 | 2008 |
| Metric | PAR | ABUS |
|---|---|---|
| Price | $14.72 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $33.20 | $5.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $455,547,000.00 | $14,083,000.00 |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | $239.71 |
| P/E Ratio | ★ N/A | $4.95 |
| Revenue Growth | 30.16 | ★ 128.21 |
| 52 Week Low | $11.59 | $3.04 |
| 52 Week High | $72.15 | $5.10 |
| Indicator | PAR | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 45.31 |
| Support Level | $12.32 | $4.17 |
| Resistance Level | $14.84 | $4.62 |
| Average True Range (ATR) | 0.91 | 0.16 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 65.32 | 46.23 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.